While it has been established that H3K27M gene mutation correlates with a poorer clinical outcome in PBT (Lu et al., 2018; Panditharatna et al., 2018), ours is the first report to show the expression of H3K27M histone protein in the CSF, which is likely to derive from dying tumour cells. Here, H2BC12L is linked to neoplasm.